"CABG is quite far down on the list of potential indications for ATryn"
Well you can see why I am curious. Usually the choice of indication is driven by patient need; or cost of development, etc. Trials adding up to 100 patietns - that's hardly an order of magitude compared to 31 patients. I can't help thinking that perhaps there is eitehr an efficacy or safety issue.
The "trend against safety" - I was referring to the fact that the 2 refernced trials ('98 I think) both had higher adverse events in the active arms relative to the control arms - at least that's what I think I see. Not "significant" of course, as you say.
Market Data 
Markets 
AI
